Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Cutaneous Lymphangiosis Carcinomatosa in Lung Cancer.

Deutsches Arzteblatt international·2026
Same author

Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms".

Journal of the American Academy of Dermatology·2026
Same author

Bidirectional association between immunobullous diseases and obsessive-compulsive disorder including excoriation disorder.

Archives of dermatological research·2026
Same author

Diagnosis of immunobullous diseases in underrepresented groups: an all of us database study.

Archives of dermatological research·2026
Same author

International development of Investigator Global Assessment scores for pemphigus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo.

Biomolecules·2026
Same journal

Shallow Cuts, Deeper Issues: The Primacy of Deep Margins in Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same journal

Management Patterns and Repigmentation Outcomes in Pediatric Segmental Versus Non-segmental Vitiligo: A Single-center Retrospective Study (2015-2024).

The British journal of dermatology·2026
Same journal

Quality-of-Life Measurement in Migrants and Other Vulnerable Groups: Experience with Skindex-16 in Malta and Lebanon.

The British journal of dermatology·2026
Same journal

Does loss of chromosome Y in blood contribute to the sex disparity of dermatitis and eczema at older ages?

The British journal of dermatology·2026
Same journal

Soluble CD83 reverses alopecia areata via IDO-mediated Treg cell activation.

The British journal of dermatology·2026
Same journal

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
関連記事をすべて見る

関連する実験動画

Updated: May 5, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K

アンチ-p200 ペンフィゴイド

Michael Kasperkiewicz1, Manuela Pigors2, Maike M Holtsche2,3

  • 1Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

The British journal of dermatology
|August 25, 2025
PubMed
まとめ
この要約は機械生成です。

抗p200ペンフィゴイドは 自身免疫性水泡性疾患です 現在の証拠によると,ラミニンβ4が主な標的抗原であり,この状態の診断と理解を助けます.

さらに関連する動画

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

276

関連する実験動画

Last Updated: May 5, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

276

科学分野:

  • 皮膚科
  • 免疫学
  • 自己免疫性ブール病

背景:

  • 抗p200ペムフィゴイドは 膀と侵食を伴う自己免疫性突発性疾患である.
  • 臨床的特徴は,ブルラス・ペムフィゴイドおよびエピダーモリシス・ブルロサ・アクシータと共通している.
  • オートアンチボディは,皮膚と表皮の交差点にある200 kDaのタンパク質を標的にします.

研究 の 目的:

  • アンチ-p200ペンフィゴイドに関する現在の知識をまとめます.
  • 疫学,臨床表現,診断,病理生理学をレビューする.
  • この自己免疫疾患の治療戦略について

主な方法:

  • アンチp200ペンフィゴイドに関する既存の文献のレビュー
  • 間接免疫光顕微鏡を含む診断方法の分析
  • 標的抗原の評価:ラミニン γ1とラミニン β4.

主要な成果:

  • ラミニンβ4は,最も最近の,おそらく病理学的に重要な自己抗原であると特定されています.
  • 標準化された抗ラミニンβ4IgG検査は診断を容易にする.
  • in vitroおよびex vivoデータは,ラミニンβ4の役割を支持しているが,in vivoデータは待機中である.

結論:

  • 抗p200ペンフィゴイドの診断は,抗ラミニンβ4IgG検出の可用性によって強化されます.
  • ラミニンβ4は重要な自己抗原と考えられていますが,さらなるin vivo研究が必要です.
  • この病気の総合的な理解は,患者の管理に役立ちます.